Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326530 | 1.00 | THRB (0.32) | THRBTGFBR1OR51E2CYP3A4MAPK1 | |
| SCHEMBL6331659 | 1.00 | THRB (0.32) | THRBTGFBR1OR51E2CYP3A4MAPK1 | |
| SCHEMBL34469833 | 0.90 | ALDH1A1 (0.31) | — | |
| SCHEMBL5146478 | 0.86 | PTPN1 (0.33) | — | |
| SCHEMBL2223572 | 0.86 | PTPN1 (0.33) | — | |
| SCHEMBL5148636 | 0.86 | PTPN1 (0.33) | — | |
| SCHEMBL5942917 | 0.84 | GPR84 (0.34) | — | |
| SCHEMBL3409134 | 0.84 | GPR84 (0.34) | — | |
| SCHEMBL3407667 | 0.84 | GPR84 (0.34) | — | |
| SCHEMBL2840047 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844158-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Xenon Pharmaceuticals Inc. (CA) | 2021-07-07 | — | — | EP | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047312-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| WO-2015051052-A2 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-1003721-B1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-20060205837-A1 | Compounds which can be activated by actinic radiation and contain urethane groups, method for the production thereof and use of the same | BASF COATINGS AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6759426-B2 | RESPIRATORY SYSTREM DISORDERS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISORDERS | PFIZER INC | 2004-07-06 | — | — | US | disclosed |
| WO-2003061653-A9 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LTD (GB) | 2003-12-24 | — | — | WO | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| US-4177342-A | FROM CARBAMATE(URETHANE)-CONTAINING ALCOHOLS AND POLYISOCYANATES | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | THRB 791/4885TGFBR1 3992/4885OR51E2 3843/4885 |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | THRB 1239/4885TGFBR1 3418/4885OR51E2 1340/4885 |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | THRB 2980/4885TGFBR1 674/4885OR51E2 4568/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | THRB 791/4885TGFBR1 3992/4885OR51E2 3843/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | THRB 1580/4885TGFBR1 3679/4885OR51E2 1537/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | THRB 1239/4885TGFBR1 3418/4885OR51E2 1340/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | THRB 1580/4885TGFBR1 3679/4885OR51E2 1537/4885 |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | THRB 2980/4885TGFBR1 674/4885OR51E2 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.